Key Laboratory for Food Microbial Technology of Zhejiang Province, Department of Biotechnology, Zhejiang Gongshang University, Hangzhou, Zhejiang, 310018, People's Republic of China.
Appl Microbiol Biotechnol. 2019 Feb;103(4):1573-1588. doi: 10.1007/s00253-018-09580-3. Epub 2019 Jan 4.
Helicobacter pylori is a highly prevalent human pathogen responsible for chronic inflammation of the gastric tissues, gastroduodenal ulcers, and cancer. The treatment includes a pair of antibiotics with a proton pump inhibitor PPI. Despite the presence of different treatments, the infection rate is still increasing both in developed and developing states. The challenge of treatment failure is greatly due to the resistance of H. pylori to antibiotics and its side effects. Probiotics potential to cure H. pylori infection is well-documented. Probiotics combined with conventional treatment regime appear to have great potential in eradicating H. pylori infection, therefore, provide an excellent alternative approach to manage H. pylori load and its threatening disease outcome. Notably, anti-H. pylori activity of probiotics is strain specific,therefore establishing standard guidelines regarding the dose and formulation of individual strain is inevitable. This review is focused on probiotic's antagonism against H. pylori summarizing their three main potential aspects: their efficiency (i) as an alternative to H. pylori eradication treatment, (ii) as an adjunct to H. pylori eradication treatment and (iii) as a vaccine delivery vehicle.
幽门螺杆菌是一种高度流行的人类病原体，可导致胃组织的慢性炎症、胃十二指肠溃疡和癌症。治疗包括一对抗生素和质子泵抑制剂（PPI）。尽管有不同的治疗方法，但在发达国家和发展中国家，感染率仍在上升。治疗失败的挑战很大程度上是由于幽门螺杆菌对抗生素的耐药性及其副作用。益生菌治愈幽门螺杆菌感染的潜力已有充分的记录。益生菌与传统治疗方案联合使用似乎具有根除幽门螺杆菌感染的巨大潜力，因此为管理幽门螺杆菌负荷及其威胁性疾病结果提供了一种极好的替代方法。值得注意的是，益生菌对幽门螺杆菌的抗活性是菌株特异性的，因此制定关于单个菌株的剂量和配方的标准指南是必不可少的。本综述重点关注益生菌对幽门螺杆菌的拮抗作用，总结了它们的三个主要潜在方面：（i）作为幽门螺杆菌根除治疗的替代方法，（ii）作为幽门螺杆菌根除治疗的辅助手段，（iii）作为疫苗传递载体。
